ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.
Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.
Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.
Suven Life Sciences will hold a board meeting on August 6, 2026, to consider and approve its unaudited financial results for the quarter ending June 30, 2026.
Suven Life Sciences has issued a notice for its 37th Annual General Meeting on August 25, 2026. The agenda includes adopting financial statements and approving a related party transaction.
Suven Life Sciences has provided a web-link to its Annual Report for FY 2025-2026. This notice informs shareholders whose email addresses are not registered.
Suven Life Sciences Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report details the company's operational, employee, and ESG metrics.
Suven Life Sciences Limited has issued a notice for its 37th Annual General Meeting scheduled for August 25, 2026.
Suven Life Sciences Ltd has filed its quarterly shareholding pattern. The document provides details on the current stake distribution between promoters and public shareholders.
Promoter Jasti Property and Equity Holdings reported a dilution of stake from 70.08% to 65.47% due to company-level ESOP and warrant conversions.
Suven Life Sciences allotted 271,970 equity shares under its Employee Stock Option Scheme. The shares were admitted for trading on BSE and NSE effective July 3, 2026.
Suven Life Sciences will present five posters at AAIC-2026 in London, updating its Phase-3 Masupirdine and Phase-2 Usmarapride programs. It seeks partnerships for its CNS pipeline.
Suven Life Sciences' Board approved converting warrants into 1.85 crore shares for Rs.24.88 Cr. It also reappointed an Independent Director for a 5-year term.
SUVEN Life Sciences Ltd re‑appointed Vajja Sambasiva Rao as a non‑executive independent director. The appointment is effective from 21 Jan 2027 for a 60‑month term.
SUVEN Life Sciences Limited re-appointed Mr. Vajja Sambasiva Rao as Non-Executive Independent Director for 60 months. The board meeting was held on 08‑07‑2026.
SUVEN Life Sciences raised about ₹248.84 Crore through a preferential issue of 18.57 million equity shares at Rs 134 each. Post‑issue paid‑up capital is now 282.56 million shares.
Suven Life Sciences raised ₹248.84 Crore via preferential allotment of 1.85 Crore equity shares at ₹134 each. Paid‑up capital now stands at 282.56 Million shares.
Suven Life Sciences announced three poster presentations on Samelisant at the SLEEP-2026 meeting in Baltimore. The disclosure highlights its progressing CNS pipeline and potential partnership opportunities.
Suven Life Sciences reported positive interim safety and analysis results for its Masupirdine Phase 3 study. The trial remains unchanged with enrollment completion expected by September 2026.
Suven Life Sciences received a tax rectification order disallowing certain R&D deductions for AY 2020-21. The company plans to appeal and anticipates no material financial impact.
Suven Life Sciences clarified that recent trading volume surges are based on market speculation. The company confirmed no undisclosed material events currently impact its security.
Suven Life Sciences Limited released its quarterly Monitoring Agency Report for the ₹857.64 Crore preferential issue. CRISIL confirmed fund utilization aligns with stated objects for March 2026.
Suven Life Sciences granted 1,33,200 stock options at ₹55 per share under its 2020 ESOP scheme. Options vest over three years starting May 2027.
Suven Life Sciences Ltd reported revenue from operations of ₹1.5 Cr (+0.0% YoY) and a net loss of ₹45.6 Cr for Q4 FY26.
Suven Life Sciences reported audited financial results for FY26. The Board also noted a fine waiver from BSE and scheduled its 37th AGM for August 2026.
Suven Life Sciences reached a 76% enrollment milestone for its Phase 3 Alzheimer's trial. Data readout is expected by April 2027, marking significant clinical progress.
Suven Life Sciences Ltd has scheduled a board meeting on May 13, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window remains closed until May 15, 2026.
Suven Life Sciences Ltd clarified to the BSE and NSE that there is no undisclosed material information affecting recent price and volume behavior. The company attributes the recent movement in its security to market speculation. All significant information under Regulation 30 of SEBI LODR has been previously disclosed.